Eterna Therapeutics ERNA 深 沪
等待开盘 07-09 09:30:00 美东时间
5.96
-0.240
-3.87%
华盛通- 最 高6.425
- 今 开6.23
- 成交量 7966股
- 最 低 5.935
- 昨 收 6.20
- 总市值 695.13万
- 52周最高 71.4975
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 3.1829
- 委 比 0.00%
- 总股本 116.63万
- 历史最高 4762500.00
- 量 比 0.63
- 振 幅 7.90%
- 历史最低 3.355
- 每 手 1
- 风险率 15.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eterna Therapeutics announces finance leadership transition and search
An update from Eterna Therapeutics ( ($ERNA) ) is now available. On June 22, 20...
06-27 05:09
Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progress across manufacturing, regulatory and clinical development activities supporting ERNA-101, the Company's lead on...
06-17 20:47
Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study Initiation
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the development of ERNA-101,
05-27 20:13
Ernexa Stock Is Jumping Today: What's Going On?
Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA‑101 in ovarian cancer.
05-13 03:22
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Agilon Health (NYSE:AGL) shares moved upwards by 115.7% to $60.08 duri...
05-08 01:05
Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data
Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade.
05-06 22:52
Ernexa Therapeutics Announces 1-For-25 Reverse Stock Split Effective May 4
The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number for
04-30 21:02
Ernexa Therapeutics ERNA-101 Shows Durable Tumor Regression With PD-1 Blockade In Preclinical Ovarian Cancer Models; IND Submission Planned Q3 2026; First-In-Human Trial Expected Q4 2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancerIND submission for ERNA-101 expected in Q3 2026 with first-in-human
03-31 20:58
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
